



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C12N 15/00, C07H 21/04, 21/02, C07K 1/00, C12P 21/06, A01N 63/00, 43/04, A61K 45/00, 39/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/46361</b> <b>(43) International Publication Date:</b> 10 August 2000 (10.08.00)
<b>(21) International Application Number:</b> PCT/US00/02740 <b>(22) International Filing Date:</b> 2 February 2000 (02.02.00) <b>(30) Priority Data:</b> 60/118,287 2 February 1999 (02.02.99) US <b>(71) Applicant (for all designated States except US):</b> OREGON HEALTH SCIENCES UNIVERSITY [US/US]; 3181 S.W. Sam Jackson Park Road, L335, Portland, OR 97201-3098 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> JOHNSON, David, C. [CA/US]; 7510 S.W. Kelly, Portland, OR 97219 (US). TOMAZIN, Roman [CA/US]; 911 S.W. Broadway Drive #5, Portland, OR 97201 (US). BONAME, Jessica [CA/GB]; 11 Cross Street, Cambridge CB1 2HW (GB). MEGDE, Nagendra, R. [IN/US]; 1011 S.W. Curry Street, Apt. 10, Portland, OR 97201 (US). <b>(74) Agent:</b> NOONAN, William, D.; Klarquist, Sparkman, Campbell, Leigh & Winston, LLP, Suite 1600 - One World Trade Center, 121 S.W. Salmon Street, Portland, OR 97204 (US).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.          Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> INHIBITION OF THE MHC CLASS II ANTIGEN PRESENTATION PATHWAY AND PRESENTATION TO CD4+ CELLS		
<b>(57) Abstract</b>  <p>The human cytomegalovirus (HCMV) protein, that was previously shown to block the MHC class I antigen presentation pathway, has been shown herein to block the MHC class II pathway. This is surprising because the class I and class II proteins are not homologous. US2 caused degradation of class II-<math>\alpha</math> proteins and also class II-DM-<math>\alpha</math>, part of an enzymatic complex required for loading of antigenic peptides. In this way, US2 has a double inhibitory effect on the MHC class II pathway. US2 expression in cells effectively blocked presentation of antigens to CD4+ T lymphocytes. US2, or soluble variants thereof, can be used to reduce inappropriate immune responses directed to vectors, or expressed transgenes. In addition, such molecules can be used to block immunity to transplanted cells or organs in autoimmune diseases.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/02740**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/320.1, 69.1; 536/23.1, 24.1; 424/93.21, 184.1; 530/350; 514/44;

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN,

SEARCH TERMS: HCMV US2 OR US11, US2 PROTEIN, MHC2 OR MHC11 MOLECULES.

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database Swissprot 38 on gencore, No. P09713, Weston, K. et al. 'Sequence of the short unique region, short repeats, and part of the long repeats of human Cytomegalovirus,' J. Mol. Biol. 1986, Vol. 192 pages 177-208, see entire document.	6-7, 23
X	Database A-gene seq 36 on gencore 4.5, No. R34706, Glick, D.L. et al. 'Purified DNA encoding eukaryotic nad cyclase-useful for prodn. Of cyclic adenosine di: phosphate ribose from NAD,' US 5202426 A, 13 April 1993, see cols 15-18.	23
Y	Database Pir-62 on gencore 4.5, No. E26078, SO9916, Weston, R. et al. 'Sequence of the short unique region, short repeats, and part of the long repeat'. J. Mol. Biol. 1986, 192, pages 177-208, see entire document.	25



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

21 APRIL 2000

Date of mailing of the international search report

30 MAY 2000

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

YVETTE CONNELL

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/02740

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,843,458 A (JONES et al.) 01 December 1998 (01/12/98), see entire document.	1-38
A	WO 97/32605 A1 (MASSACHUSETTS INSTITUTE OF TECHNOLOGY) 12 September 1997(12/09/97), see entire document.	1-38

**INTERNATIONAL SEARCH REPORT**

International application No.  
PCT/US00/02740

A. CLASSIFICATION OF SUBJECT MATTER:  
IPC (7):

C12N 15/00; C07H 21/04, 21/02; C07K 1/00; C12P 21/06; A01N 63/00, 43/04; A61K 45/00, 39/00;

A. CLASSIFICATION OF SUBJECT MATTER:  
US CL :

435/320.1, 69.1; 536/23.1, 24.1; 424/93.21, 184.1; 530/350; 514/44;

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents  
 United States Patent and Trademark  
 Office  
 Box PCT  
 Washington, D.C.20231  
 ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

<b>Date of mailing (day/month/year)</b> 04 October 2000 (04.10.00)	
<b>International application No.</b> PCT/US00/02740	<b>Applicant's or agent's file reference</b> 899-54203
<b>International filing date (day/month/year)</b> 02 February 2000 (02.02.00)	<b>Priority date (day/month/year)</b> 02 February 1999 (02.02.99)
<b>Applicant</b> JOHNSON, David, C. et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

24 August 2000 (24.08.00)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland  Facsimile No.: (41-22) 740.14.35	Authorized officer  Pascal Piriou  Telephone No.: (41-22) 338.83.38
---	---

09/890806


14

## PATENT COOPERATION TREATY

## PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)



Applicant's or agent's file reference 899-54203	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US00/02740	International filing date (day/month/year) 02 FEBRUARY 2000	Priority date (day/month/year) 02 FEBRUARY 1999
International Patent Classification (IPC) or national classification and IPC Please See Supplemental Sheet.		
Applicant OREGON HEALTH SCIENCES UNIVERSITY		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 4 sheets.

☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 0 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of report with regard to novelty, inventive step or industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand 24 AUGUST 2000	Date of completion of this report 22 OCTOBER 2001
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer <i>Dorthea Lawrence</i> ANNE MARIE BECKERLEG
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US00/02740

## 1. Basis of the report

1. With regard to the **elements** of the international application: \*

- ☒ the international application as originally filed
- ☒ the description:  
pages 1-31, as originally filed  
pages NONE, filed with the demand  
pages NONE, filed with the letter of \_\_\_\_\_
- ☒ the claims:  
pages 32-35, as originally filed  
pages NONE, as amended (together with any statement) under Article 19  
pages NONE, filed with the demand  
pages NONE, filed with the letter of \_\_\_\_\_
- ☒ the drawings:  
pages 1-8, as originally filed  
pages NONE, filed with the demand  
pages NONE, filed with the letter of \_\_\_\_\_
- ☒ the sequence listing part of the description:  
pages 1-5, as originally filed  
pages NONE, filed with the demand  
pages NONE, filed with the letter of \_\_\_\_\_

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language \_\_\_\_\_ which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in printed form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☒ The amendments have resulted in the cancellation of:

- ☒ the description, pages NONE
- ☒ the claims, Nos. NONE
- ☒ the drawings, sheets/fig NONE

5. ☐ This report has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).\*\*

\* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

\*\*Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.



## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US00/02740

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

## 1. statement

Novelty (N)	Claims	<u>5-7, 9, 14, 16-38</u>	YES
	Claims	<u>1-4, 8, 10-13, 15</u>	NO
Inventive Step (IS)	Claims	<u>5-7, 9, 14, 16-38</u>	YES
	Claims	<u>1-4, 8, 10-13, 15</u>	NO
Industrial Applicability (IA)	Claims	<u>1-38</u>	YES
	Claims	<u>NONE</u>	NO

## 2. citations and explanations (Rule 70.7)

Claims 1-4, 8, 10-13, and 15 lack novelty under PCT Article 33(2) as being anticipated by WO 97/32605 12 September 1997, hereafter referred to as Ploegh et al. The claims recite vectors encoding HCMV US2 and methods of inhibiting the recognition of cellular tissue or the methods of preventing or treating autoimmune disease by administering an effect amount of said vector. The claims further recite wherein the vector is a viral vector and wherein the US2 has not been mutated to recognize MHC class II.

Ploegh et al. teaches vectors, including adenoviral or vaccinia viral vectors, encoding wild type HCMV US2, and the administration of said vectors to mammals to prevent autoimmune disease (Ploegh et al., see pages 8-10, especially page 10, and page 27, claims 25-28). It is noted that while Ploegh et al. does not specifically teach that US2 has MHC class II inhibiting activity, such activity is inherent to the wild type US2 protein. Thus, by teaching all the limitations of the claims, Ploegh et al. anticipates the instant invention.

Claims 1-4, 8, and 10-11 lack novelty under PCT Article 33(2) as being anticipated by Machold, R.P. et al., J. Exp. Med., January 20, 1997, Vol. 185, pages 363-366. The claims recite vectors encoding HCMV US2 and methods of inhibiting the recognition of cellular tissue by CD4+ and CD8+ T cells by administering an effect amount of said vector. The claims further recite wherein the vector is a viral vector and wherein the US2 has not been mutated to recognize MHC class II.

Machold et al. teaches vaccinia virus vectors encoding wild type HCMV US2 and the transfection of mammalian cells with the vaccinia virus resulting in the degradation of MHC class I molecules which in turn inhibits recognition of the transfected cells by T cells (Machold et al., page 364, Figure 1, and page 366). It is noted that while Machold et al. does not specifically teach that US2 has MHC class II inhibiting activity, such activity is inherent to the wild type US2 protein. Thus, by teaching all the limitations of the claims, Machold et al. anticipates the instant invention.

(Continued on Supplemental Sheet.)

**Supplemental Box**

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

**CLASSIFICATION:**

The International Patent Classification (IPC) and/or the National classification are as listed below:

IPC(7): C12N 15/00; C07H 21/04, 21/02; C07K 1/00; C12P 21/06; A01N 63/00, 43/04; A61K 45/00, 39/00; and US Cl.: 435/320.1, 69.1; 536/23.1, 24.1; 424/93.21, 184.1; 530/350; 514/44;

**V. 2. REASONED STATEMENTS - CITATIONS AND EXPLANATIONS (Continued):**

Claims 5, 9, 14, and 16-38 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the administration of HCMV US2 protein to inhibit cellular immune responses or treat disease, or teach a soluble US2 variant.

Claims 1-38 meet the criteria set out in PCT Article 33(4) for industrial applicability.

## ----- NEW CITATIONS -----

MACHOLD, R. P. et al. "The HCMV gene products US11 and US2 differ in their ability to attack allelic forms of murine major histocompatibility complex (MHC) class I heavy chains." J. Exp. Med. January 20, 1997. Vol. 185. pages 363-366, see especially page 364.